Compare EPAM Systems Inc (EPAM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Neurocrine Biosciences Inc — how do they compare? EPAM Systems Inc trades at $113.24 (market cap $5.87B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.4× EPAM Systems Inc's market cap, and EPAM Systems Inc is more actively traded (847,420 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EPAM | NBIX | |
|---|---|---|
Market Cap | $5.87B | $14.36B |
Volume | 847,420 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $221.40 | $185.50 |
52-Week Low | $76.04 | $123.10 |
Typical Hold Time | 37 Days | 23 Days |
Enterprise Value | $5.24B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.86, up 5.11% today, with strong technical momentum as the stock approaches resistance near $115. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.46B in 2025, though net margins compressed to 6.92%. Recent news highlights EPAM's cloud infrastructure achievements and activist investor pressure for share buybacks.
The outlook remains cautiously optimistic with a consensus price target of $119 offering 4.5% upside. Key risks include North American growth slowdown and AI disruption to legacy services. Analyst sentiment is predominantly bullish (59% Buy ratings), but investors should monitor Q3 earnings and management's response to shareholder value concerns.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
